SEC Form 4 · accession 0001182489-15-000423
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew K Fust
Director
Period of report
Mar 19, 2015
Accepted (ET)
Mar 23, 2015 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 19, 2015 | M | 6,319 | $21.00 | A | 11,319 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $21.00 | Mar 19, 2015 | M | 6,319 | D | — | Jan 29, 2024 | Common Stock | 6,319 | 11,181 | D |
Explanation of responses
- F1The option shall vest with respect to 1/36th of the shares monthly from the grant date of January 30, 2014 such that the option shall be fully vested on the third anniversary of the grant date.